GlaxoSmithKline's central nervous system treatment drug Rapidone approved for new indications for bipolar disorder

Shanghai, China, March 3, 2021-GlaxoSmithKline (hereinafter referred to as "GSK"), the world's leading multinational healthcare company, today announced that Rapidone (generic name: Lamotrigine Dispersible Tablets) has been awarded the National Medicines of China supervision and management Bureau of new indications approved for the control of adult patients with bipolar disorder or mood episode recurrence resurgence [1].

Ms.

Diagnosis and treatment of bipolar disorder faces many challenges, and the "three rates of identification, diagnosis , and treatment are all low"

Bipolar disorder is a common clinical disease.

In my country, due to the public's lack of disease awareness of bipolar disorder, the proportion of patients who go to the hospital for formal diagnosis is not high, which leads to a low recognition rate and diagnosis rate.

Professor Wang Gang, Dean of Beijing Anding Hospital Affiliated to Capital Medical University, Director of the National Research Center for Mental and Psychological Diseases, and Director of the Depression Treatment Center, said: "The current treatment methods for bipolar disorder in China mainly include medication, psychotherapy, and supportive treatment.

Rapidone is approved to treat bipolar disorder, helping to improve the standardization of bipolar disorder in my country

In addition to the difficulty of identification and diagnosis, another major challenge currently faced by patients with bipolar disorder is the limitations of treatment options.

Professor Wang Gang believes: “It can be said that the treatment of bipolar depression is the main challenge currently facing the clinical treatment of bipolar disorder.

In fact, Ribitone (active ingredient: Lamotrigine) for the treatment of bipolar disorder has been widely recognized and used abroad.

In view of the scientifically proven clinical efficacy, including the American Psychiatric Association guidelines, the World Federation of Biological Psychiatry guidelines, the British Psychopharmacological Association guidelines, the Canadian Mood and Anxiety Treatment Steering Group/International Bipolar Disorder Society, China Bipolar Disorder Prevention Guidelines, etc.

About GSK: GSK is a science-oriented global healthcare company that aims to help people do more, feel more comfortable, and live longer.

[References] [1] Rapidone has been approved for new indications: "This product is used to control the recurrence or resurgence of emotional episodes in adults with bipolar disorder.